{"ATC Code":["M - Musculo-skeletal system","M - Musculo-skeletal system","M01 - Antiinflammatory and antirheumatic products","M01A - Antiinflammatory and antirheumatic products, non-steroids","M01AE - Propionic acid derivatives","M01AE09 - Flurbiprofen","M02 - Topical products for joint and muscular pain","M02A - Topical products for joint and muscular pain","M02AA - Antiinflammatory preparations, non-steroids for topical use","M02AA19 - Flurbiprofen","QM - Musculo-skeletal system","QM - Musculo-skeletal system","QM01 - Antiinflammatory and antirheumatic products","QM01A - Antiinflammatory and antirheumatic products, non-steroids","QM01AE - Propionic acid derivatives","QM01AE09 - Flurbiprofen","QM02 - Topical products for joint and muscular pain","QM02A - Topical products for joint and muscular pain","QM02AA - Antiinflammatory preparations, non-steroids for topical use","QM02AA19 - Flurbiprofen","QR - Respiratory system","QR02 - Throat preparations","QR02A - Throat preparations","QR02AX - Other throat preparations","QR02AX01 - Flurbiprofen","QS - Sensory organs","QS01 - Ophthalmologicals","QS01B - Antiinflammatory agents","QS01BC - Antiinflammatory agents, non-steroids","QS01BC04 - Flurbiprofen","R - Respiratory system","R02 - Throat preparations","R02A - Throat preparations","R02AX - Other throat preparations","R02AX01","R02AX01 - Flurbiprofen","S - Sensory organs","S01 - Ophthalmologicals","S01B - Antiinflammatory agents","S01BC - Antiinflammatory agents, non-steroids","S01BC04 - Flurbiprofen"],"Absorption, Distribution and Excretion":"Fluribiprofen is rapidly and almost completely absorbed following oral administration. Peak plasma concentrations are reached 0.5 - 4 hours after oral administration.","Aliases":["Ansaid","Froben","Antadys","2-(2-fluorobiphenyl-4-yl)propanoic acid","Cebutid","Zepolas","Flubiprofen","Flurbiprofene","Flurbiprofeno","3-Fluoro-4-phenylhydratropic acid","Flurbiprofenum","BTS-18322","U-27182","BTS 18322","2-Fluoro-α-methyl-(1,1'-biphenyl)-4-acetic acid","2-Fluoro-α-methyl-4-biphenylacetic acid","BTS 18,322","NSC-757037","CHEBI:5130","U-27,182","Dtxcid8017231","NSC685701","Fluriproben","(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-α-methyl-, (+-)-","Froben Sr","Strefen","Novo Flurprofen","Nu Flurbiprofen","Apo Flurbiprofen","Rinol-STroche","ratio Flurbiprofen","2-Fluoro-α-methyl(1,1'-biphenyl)-4-acetic acid","Antiphlamine Pain Relieving","M01AE09","M02AA19","R02AX01","S01BC04","BTS18322","(2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid","225-827-6","Flurofen","Adfeed","Ocufen","Mfcd00079303","2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid","FP 70","Stayban","51543-38-5","U 27182","2-(2-Fluoro-4-biphenylyl)propionic acid","U 27,182","Prestwick1_000917","(.+/-.)-Flurbiprofen","2-(2-Fluoro-1,1'-biphenyl-4-yl)propanoic acid","CHEMBL563","[+/-]-2-Fluoro-α-methyl-4-biphenylacetic acid","Mls000040873","2-(3-fluoro-4-phenyl-phenyl)propanoic acid","Flugalin","2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid","s1679","Anmetarin","Smr000042823","Yakuban","2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid","Ocuflur","2-(2-Fluorobiphenyl-4-yl)propionic Acid","CCRIS 3708","Sr-01000003043","FLP","Flurbiprofen;MPC7869","Einecs 225-827-6","Flurbiprofen; (2RS)-2-(2-Fluorobiphenyl-4-yl)propanoic acid","Flurbiprofen O","MKS-11","rac-Flurbiprofen","Spectrum5","Froben;","Flurbiprofen CRS","2-(2-Fluoro-4-biphenylyl)propanoic acid","Ncgc00016654-01","(+-)Flurbiprofen","Cas-5104-49-4","Einecs 257-262-6","[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-?-methyl-","(1)-2-Fluoro-α-methyl(1,1'-biphenyl)-4-acetic acid","Spectrum_001096","Opera_ID_777","Prestwick0_000917","Prestwick2_000917","Prestwick3_000917","Spectrum2_001025","Spectrum3_000435","Spectrum4_000558","Spectrum5_000720","F0371","Flurbiprofendl-Flurbiprofen","Epitope ID:613431","4-Biphenylacetic acid, 2-fluoro-α-methyl-","Schembl2248","BSPBio_000794","BSPBio_002050","KBioGR_001255","KBioSS_001576","Mls000028441","Mls000758198","Mls001201729","Mls001401361","Mls006011431","Mls006011931","DivK1c_000804","Spectrum1500308","SPBio_001209","SPBio_002983","BPBio1_000874","GTPL4194","orb1224876","orb1310752","Schembl10029029","HMS502I06","KBio1_000804","KBio2_001576","KBio2_004144","KBio2_006712","KBio3_001270","Sytbzmrglbwntm-uhfffaoysa-","[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-","MSK7164","Ninds_000804","HMS1570H16","HMS1920O20","HMS2051A05","HMS2090I06","HMS2091F21","HMS2097H16","HMS2232I08","HMS3259I12","HMS3268E10","HMS3370N14","HMS3371I05","HMS3393A05","HMS3414N17","HMS3649K11","HMS3655G19","HMS3678N15","HMS3714H16","HMS5079N10","Pharmakon1600-01500308","2-Fluoro-[1,1'-biphenyl]-4-(α-methyl)acetic acid","Tox21_110547","Tox21_302353","BBL010980","Bdbm50074922","CCG-40243","EBC-26294","HB3049","HY-10582R","Msk7164-100m","NSC755404","NSC757037","SBB067242","STK802101","Flurbiprofen, cyclooxygenase inhibitor","Akos004119934","Akos016340701","Msk7164-1000m","AC-8106","CCG-100759","DB00712","FF23507","KS-5035","NC00009","NC00563","NSC 757037","NSC-685701","NSC-755404","2(2-Fluoro-4-biphenylyl)propionic acid","Flurbiprofen for peak identification CRS","Idi1_000804","Ncgc00018157-03","Ncgc00018157-04","Ncgc00018157-05","Ncgc00018157-08","Ncgc00018157-11","Ncgc00018157-13","Ncgc00025287-03","Ncgc00025287-04","Ncgc00255457-01","HY-10582","Nci60_030812","SY057091","2 -(2-fluoro-4-biphenylyl)propionic acid","2-(2-fluoro-4-biphenylyl)-propionic acid","2-(2-fluoro-biphenyl-4-yl)propionic acid","Sbi-0051387.p003","DB-051888","2-(2-fluoro-biphenyl-4-yl)-propionic acid","AB00051999","F4481","Flurbiprofen Solution in Methanol, 100ug/mL","NS00003058","ST50825909","α-methyl-2-fluoro-4-biphenylylacetic acid","Flurbiprofen Solution in Methanol, 1000ug/mL","2-(2-fluorobiphenyl-4-yl)propionic acid","Bim-0051387.0001","C07013","D00330","Ab00051999-17","Ab00051999_18","En300-7479231","2-fluoro--methyl-(1,1'-biphenyl)-4-acetic acid","Ao-295/42284050","F463477","(.+/-.)-2-(2-Fluoro-4-biphenylyl)propionic acid","(r/s)-2-fluoro-α-methyl-4-biphenylacetic acid","Sr-01000003043-2","Sr-01000003043-5","Sr-01000003043-6","2-(2-fluoro-[1,1''-biphenyl-4-yl])propanoic acid","2-(2-Fluoro[1,1'-biphenyl]-4-yl)propanoic acid #","Brd-a86044036-001-05-9","Brd-a86044036-001-26-5","Brd-a86044036-001-27-3","Sr-01000003043-14","(.+/-.)-2-Fluoro-α-methyl-4-biphenylacetic acid","2-fluoro-α-methyl-(1,1''-biphenyl)-4-acetic acid","2-Fluoro-α-methyl-[1,1'-biphenyl]-4-a cetic acid","2-Fluoro-I\u003c\u003c-methyl-[1,1'-biphenyl]-4-a cetic acid","Z2216885233","[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-","Flurbiprofen, European Pharmacopoeia (EP) Reference Standard","(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-α-methyl-","[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-a-methyl-, (A+/-)-","Flurbiprofen, United States Pharmacopeia (USP) Reference Standard","[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl-, (.+/-.)-","2-[2-Fluoro-[1,1 inverted exclamation mark -biphenyl]-4-yl]propanoic Acid","Flurbiprofen, 2-(2-Fluorobiphenyl-4-yl)propionic acid, 3-Fluoro-4-phenylhydratropic acid","Flurbiprofen, Pharmaceutical Secondary Standard; Certified Reference Material","2-Fluoro-4-Iodo-1-isothiocyanatobenzene; 2-Fluoro-4-iodo-1-isothiocyanatobenzene; 2-Fluoro-4-iodophenyl isothiocyanate;","InChI=1/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)"],"Biological Half-Life":"R-flurbiprofen, 4.7 hours; S-flurbiprofen, 5.7 hours","CAS":"5104-49-4","ChemicalClasses":["alcohol"],"Chirality":"racemic","Classes":["Nonsteroidal anti-inflammatory drug"],"DTXSID":"0037231","Drug Classes":["Breast Feeding","Lactation","Milk, Human","Analgesic Agents","Anti-inflammatory Agents, Nonsteroidal"],"Drug Indication":"Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.","EliminationHalfLife":"4.7 – 5.7 hours","Esters":[],"European Community (EC) Number":"225-827-6","FDA Pharmacological Classification":[{"Name":"FDA UNII","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"String":"5GRO578KLP"}]}},{"Name":"Active Moiety","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"String":"FLURBIPROFEN"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"String":"Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"String":"Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"String":"Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug"}]}},{"Name":"FDA Pharmacology Summary","ReferenceNumber":39,"Value":{"StringWithMarkup":[{"Markup":[{"Extra":"CID-3394","Length":12,"Start":0,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/Flurbiprofen"},{"Extra":"CID-3394","Length":12,"Start":82,"Type":"PubChem Internal Link","URL":"https://pubchem.ncbi.nlm.nih.gov/compound/flurbiprofen"}],"String":"Flurbiprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of flurbiprofen is as a Cyclooxygenase Inhibitor."}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":65,"Value":{"StringWithMarkup":[{"String":"FLURBIPROFEN"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":65,"Value":{"StringWithMarkup":[{"String":"Cyclooxygenase Inhibitors [MoA]; Nonsteroidal Anti-inflammatory Drug [EPC]; Anti-Inflammatory Agents, Non-Steroidal [CS]"}]}},{"Name":"Non-Proprietary Name","ReferenceNumber":66,"Value":{"StringWithMarkup":[{"String":"FLUBIPROFEN"}]}},{"Name":"Pharmacological Classes","ReferenceNumber":66,"Value":{"StringWithMarkup":[{"String":"Anti-Inflammatory Agents, Non-Steroidal [CS]; Nonsteroidal Anti-inflammatory Drug [EPC]; Cyclooxygenase Inhibitors [MoA]"}]}}],"Formating":[],"HMDB ID":"HMDB0014850","HeavyAtomCount":18,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal","IUPACName":"2-(3-fluoro-4-phenylphenyl)propanoic acid","InChI":"InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)","InChIKey":"SYTBZMRGLBWNTM-UHFFFAOYSA-N","MeSH Headers":[{"Id":"M0008647","Link":"https://id.nlm.nih.gov/mesh/M0008647.html","Name":"Flurbiprofen","Ref":109},{"Id":"M000639966","Link":"https://id.nlm.nih.gov/mesh/M000639966.html","Name":"Froben SR","Ref":111},{"Id":"M0351586","Link":"https://id.nlm.nih.gov/mesh/M0351586.html","Name":"BTS-18322","Ref":112},{"Id":"M0351587","Link":"https://id.nlm.nih.gov/mesh/M0351587.html","Name":"Ansaid","Ref":113},{"Id":"M0478661","Link":"https://id.nlm.nih.gov/mesh/M0478661.html","Name":"Cebutid","Ref":114},{"Id":"M0478663","Link":"https://id.nlm.nih.gov/mesh/M0478663.html","Name":"Froben","Ref":115},{"Id":"M0478668","Link":"https://id.nlm.nih.gov/mesh/M0478668.html","Name":"Strefen","Ref":116},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":117},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":149},{"Id":"M0001067","Link":"https://id.nlm.nih.gov/mesh/M0001067.html","Name":"Analgesics","Ref":150},{"Id":"M0001335","Link":"https://id.nlm.nih.gov/mesh/M0001335.html","Name":"Anti-Inflammatory Agents, Non-Steroidal","Ref":151},{"Id":"M0025664","Link":"https://id.nlm.nih.gov/mesh/M0025664.html","Name":"Cyclooxygenase Inhibitors","Ref":152}],"MeSH Pharmacological Classification":[{"Id":"M0001067","Link":"https://id.nlm.nih.gov/mesh/M0001067.html","Name":"Analgesic","Ref":150},{"Id":"M0001335","Link":"https://id.nlm.nih.gov/mesh/M0001335.html","Name":"Anti-Inflammatory Agents, Non-Steroidal","Ref":151},{"Id":"M0025664","Link":"https://id.nlm.nih.gov/mesh/M0025664.html","Name":"Cyclooxygenase Inhibitor","Ref":152}],"Mechanism of Action":"Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.","Melting Point":"110-111 °C","Metabolism/Metabolites":"Hepatic. Cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4\u0026rsquo;-hydroxy-flurbiprofen. The 4\u0026rsquo;-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of inflammation.","MolecularFormula":"C\u003csub\u003e15\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eFO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"244.26 g/mol","Opticalactivity":"( + / - )","Pharmacodynamics":"Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.","Physical Description":"Solid","PubChemId":3394,"PubChemTitle":"Flurbiprofen","Record Description":["LiverTox|Analgesic|Mild-Moderate Pain|NSAID"],"Records":{"UNII":{"Impurities":["2-(4-biphenylyl)propionic acid","2-fluorobiphenyl-4-carboxylic acid","2-(2-fluoro[1,1′-biphenyl]-4-yl)-2-methylpropanedioic acid","4-acetyl-2-fluorobiphenyl","2-(2-fluorobiphenyl-4-yl)-2-hydroxypropanoic acid"]}},"RefChem":"55218","RefCount":2,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Flurbiprofen","Name":"Flurbiprofen","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q419890","Name":"Flurbiprofen","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB00712","Name":"Flurbiprofen","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3394","Name":"Flurbiprofen","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=5104-49-4","Name":"Flurbiprofen","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014850","Name":"Flurbiprofen","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07013","Name":"Flurbiprofen","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/5GRO578KLP","Name":"Flurbiprofen","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID0037231","Name":"Flurbiprofen","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3394, Flurbiprofen. Accessed October 15, 2026. \u003ca href='https://pubchem.ncbi.nlm.nih.gov/compound/3394'\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3394\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Flurbiprofen. UNII: 5GRO578KLP. Global Substance Registration System. Accessed October 15, 2026. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/5GRO578KLP\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/5GRO578KLP\u003c/a\u003e"],"SMILES":"CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O","SaltData":[{"AcidCount":1,"Amine":"Flurbiprofen","AmineCount":1,"Formula":"[Na+]","Name":"sodium","RName":"sodium","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 138.651 70.661\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h139v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m33.653.96-.002 15.24M33.651 16.2l13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m60.056 16.202-13.208 7.62M60.056 19.017l-10.77 6.214\"/\u003e\u003c/g\u003e\u003cpath d=\"m60.056 16.202 13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M73.264 39.062v-15.24M70.825 37.654V25.231\"/\u003e\u003c/g\u003e\u003cpath d=\"m73.264 39.062-13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m46.848 39.062 13.208 7.62M49.286 37.654l10.77 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"M46.848 23.822v15.24M73.264 39.062l13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m99.665 39.058-13.204 7.626M99.665 41.874l-10.767 6.218\"/\u003e\u003c/g\u003e\u003cpath d=\"m99.665 39.058 13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m112.855 61.929.007-15.249M110.417 60.521l.006-12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"M112.855 61.929 99.65 69.555\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m86.453 61.933 13.197 7.622M88.893 60.526l10.757 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m86.461 46.684-.008 15.249M73.264 23.822l10.373-5.991M33.651 16.2l-13.2 7.618\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m21.671 23.114-.002 11.751M19.232 23.114l-.002 11.751\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m21.669 34.865.001-5.876M19.23 34.865l.001-5.876\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.451 23.818-9.589-5.538\" class=\"bond\"/\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M85.023 13.7h2.875v.571h-2.196v1.471h1.982v.571h-1.982V18.7h-.679z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M20.452 37.013q-.738 0-1.173.554-.429.547-.429 1.494t.429 1.494q.435.548 1.173.548t1.167-.548q.428-.547.428-1.494t-.428-1.494q-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703t-1.685-.703q-.631-.702-.631-1.887t.631-1.887q.631-.709 1.685-.709\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M7.257 14.151q-.738 0-1.172.554-.429.547-.429 1.494 0 .946.429 1.494.434.548 1.172.548t1.167-.548.429-1.494q0-.947-.429-1.494-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.702-1.679.702-1.053 0-1.684-.702t-.631-1.887.631-1.887q.631-.709 1.684-.709M.56 13.693h.679v2.047h2.458v-2.047h.673v5h-.673v-2.381H1.239v2.381H.56z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#90e050\" d=\"m83.637 17.831-5.186 2.995\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m10.862 18.28 4.795 2.769\" class=\"hi\"/\u003e\u003c/g\u003e\u003cg class=\"mol\"\u003e\u003cg fill=\"#ab5cf2\" stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M126.909 33.427h.91l2.215 4.186v-4.186h.661v5.001h-.911l-2.221-4.185v4.185h-.654zm6.808 3.114q-.75 0-1.035.173-.286.172-.286.583 0 .327.214.524.215.19.59.19.512 0 .821-.363.31-.363.31-.97v-.137zm1.227-.25v2.137h-.613v-.571q-.215.345-.53.506-.31.16-.768.16-.578 0-.917-.321-.339-.322-.339-.863 0-.637.422-.959.429-.321 1.268-.321h.864v-.06q0-.422-.28-.655-.28-.232-.786-.232-.321 0-.625.078-.304.071-.589.226v-.566q.339-.131.654-.196.322-.066.626-.066.809 0 1.208.423.405.423.405 1.28M136.973 32.138v1.118h1.118v.343h-1.118v1.118h-.34v-1.118h-1.118v-.343h1.118v-1.118z\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"Sodium flurbiprofen","UNII":"Z5B97MU9K4"}],"Salts":["sodium"],"Scheduling":[{"gov":"Australia","ref":[],"schedule":"S2 substance"},{"gov":"Canada","ref":[],"schedule":"prescription only substance"}],"Solubility":"2.49e-02 g/L","StereoisomerData":[{"ChemicalClasses":["alcohol"],"SMILES":"C[C@@H](C(=O)O)C1=CC(F)=C(C2=CC=CC=C2)C=C1","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 113.973 70.651\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h114v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M33.251 16.2h.8M32.917 13.66h1.467M32.584 11.12h2.134M32.251 8.58h2.8M31.917 6.04h3.467M31.584 3.5h4.134M31.25.96h4.801\"/\u003e\u003c/g\u003e\u003cpath d=\"m33.651 16.2-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M21.672 23.116v11.751M19.233 23.116v11.751\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M21.672 34.867v-5.876M19.233 34.867v-5.876\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.453 23.82-9.59-5.537M33.651 16.2l13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M60.056 16.198 46.849 23.82M60.056 19.013l-10.768 6.215\"/\u003e\u003c/g\u003e\u003cpath d=\"m60.056 16.198 13.209 7.618M73.265 23.816l10.373-5.993\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m73.267 39.056-.002-15.24M70.829 37.648l-.002-12.423\"/\u003e\u003c/g\u003e\u003cpath d=\"m73.267 39.056 13.199 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m99.669 39.047-13.203 7.629M99.669 41.863l-10.765 6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m99.669 39.047 13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m112.862 61.916.005-15.249M110.424 60.508l.004-12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m112.862 61.916-13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m86.461 61.924 13.198 7.62M88.9 60.517l10.759 6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m86.466 46.676-.005 15.248M73.267 39.056l-13.206 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m46.851 39.06 13.21 7.618M49.29 37.651l10.77 6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m46.849 23.82.002 15.24\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M20.455 37.015q-.738 0-1.172.554-.429.547-.429 1.494t.429 1.494q.434.548 1.172.548.739 0 1.167-.548.429-.547.429-1.494t-.429-1.494q-.428-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703-1.053 0-1.684-.703-.631-.702-.631-1.887t.631-1.887q.631-.709 1.684-.709\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M7.257 14.155q-.738 0-1.173.554-.428.547-.428 1.494t.428 1.494q.435.548 1.173.548t1.167-.548q.429-.547.429-1.494t-.429-1.494q-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703-1.053 0-1.684-.703-.632-.702-.632-1.887t.632-1.887q.631-.709 1.684-.709M.56 13.697h.679v2.048h2.458v-2.048h.673v5h-.673v-2.381H1.239v2.381H.56z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M85.023 13.691h2.875v.572h-2.196v1.47h1.982v.572h-1.982v2.387h-.679z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m10.863 18.283 4.795 2.769\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m83.638 17.823-5.186 2.996\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"(R)-Flurbiprofen"},{"ChemicalClasses":["alcohol"],"SMILES":"C[C@H](C(=O)O)C1=CC(F)=C(C2=CC=CC=C2)C=C1","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 113.973 70.251\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h114v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"M33.251 15.8h.8l2-15.24H31.25z\" class=\"bond\"/\u003e\u003cpath d=\"m33.651 15.8-13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M21.672 22.716v11.751M19.233 22.716v11.751\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M21.672 34.467v-5.876M19.233 34.467v-5.876\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.453 23.42-9.59-5.537M33.651 15.8l13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M60.056 15.798 46.849 23.42M60.056 18.613l-10.768 6.215\"/\u003e\u003c/g\u003e\u003cpath d=\"m60.056 15.798 13.209 7.618M73.265 23.416l10.373-5.993\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m73.267 38.656-.002-15.24M70.829 37.248l-.002-12.424\"/\u003e\u003c/g\u003e\u003cpath d=\"m73.267 38.656 13.199 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m99.669 38.647-13.203 7.629M99.669 41.463l-10.765 6.22\"/\u003e\u003c/g\u003e\u003cpath d=\"m99.669 38.647 13.198 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m112.862 61.516.005-15.249M110.424 60.108l.004-12.433\"/\u003e\u003c/g\u003e\u003cpath d=\"m112.862 61.516-13.203 7.628\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m86.461 61.524 13.198 7.62M88.9 60.117l10.759 6.211\"/\u003e\u003c/g\u003e\u003cpath d=\"m86.466 46.276-.005 15.248M73.267 38.656l-13.206 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m46.851 38.66 13.21 7.618M49.29 37.251l10.77 6.212\"/\u003e\u003c/g\u003e\u003cpath d=\"m46.849 23.42.002 15.24\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M20.455 36.615q-.738 0-1.172.554-.429.547-.429 1.494t.429 1.494q.434.548 1.172.548.739 0 1.167-.548.429-.547.429-1.494t-.429-1.494q-.428-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703-1.053 0-1.684-.703-.631-.702-.631-1.887t.631-1.887q.631-.709 1.684-.709\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M7.257 13.755q-.738 0-1.173.554-.428.547-.428 1.494t.428 1.494q.435.548 1.173.548t1.167-.548q.429-.547.429-1.494t-.429-1.494q-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703-1.053 0-1.684-.703-.632-.702-.632-1.887t.632-1.887q.631-.709 1.684-.709M.56 13.297h.679v2.048h2.458v-2.048h.673v5h-.673v-2.381H1.239v2.381H.56z\"/\u003e\u003c/g\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M85.023 13.291h2.875v.572h-2.196v1.47h1.982v.572h-1.982v2.387h-.679z\" class=\"atom\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m10.863 17.883 4.795 2.768\" class=\"hi\"/\u003e\u003cpath stroke=\"#90e050\" d=\"m83.638 17.423-5.186 2.996\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"(S)-Flurbiprofen"}],"StereoisomerType":"enantiomer","Stereoisomers":["(R)-Flurbiprofen","(S)-Flurbiprofen"],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 113.969 70.661\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".8\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h114v71H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m33.653.96-.002 15.24M33.651 16.2l13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m60.056 16.202-13.208 7.62M60.056 19.017l-10.77 6.214\"/\u003e\u003c/g\u003e\u003cpath d=\"m60.056 16.202 13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M73.264 39.062v-15.24M70.825 37.654V25.231\"/\u003e\u003c/g\u003e\u003cpath d=\"m73.264 39.062-13.208 7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m46.848 39.062 13.208 7.62M49.286 37.654l10.77 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"M46.848 23.822v15.24M73.264 39.062l13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m99.665 39.058-13.204 7.626M99.665 41.874l-10.767 6.218\"/\u003e\u003c/g\u003e\u003cpath d=\"m99.665 39.058 13.197 7.622\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m112.855 61.929.007-15.249M110.417 60.521l.006-12.434\"/\u003e\u003c/g\u003e\u003cpath d=\"M112.855 61.929 99.65 69.555\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m86.453 61.933 13.197 7.622M88.893 60.526l10.757 6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m86.461 46.684-.008 15.249M73.264 23.822l10.373-5.991M33.651 16.2l-13.2 7.618\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m21.671 23.114-.002 11.751M19.232 23.114l-.002 11.751\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m21.669 34.865.001-5.876M19.23 34.865l.001-5.876\" class=\"hi\"/\u003e\u003c/g\u003e\u003cpath d=\"m20.451 23.818-9.589-5.538\" class=\"bond\"/\u003e\u003cpath fill=\"#90e050\" stroke=\"none\" d=\"M85.023 13.7h2.875v.571h-2.196v1.471h1.982v.571h-1.982V18.7h-.679z\" class=\"atom\"/\u003e\u003cpath stroke=\"none\" d=\"M20.452 37.013q-.738 0-1.173.554-.429.547-.429 1.494t.429 1.494q.435.548 1.173.548t1.167-.548q.428-.547.428-1.494t-.428-1.494q-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.703-1.679.703t-1.685-.703q-.631-.702-.631-1.887t.631-1.887q.631-.709 1.685-.709\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M7.257 14.151q-.738 0-1.173.554-.428.547-.428 1.494 0 .946.428 1.494.435.548 1.173.548t1.167-.548.429-1.494q0-.947-.429-1.494-.429-.554-1.167-.554m0-.548q1.054 0 1.679.709.631.702.631 1.887 0 1.179-.631 1.887-.625.702-1.679.702-1.053 0-1.684-.702-.632-.702-.632-1.887t.632-1.887q.631-.709 1.684-.709M.56 13.693h.679v2.047h2.458v-2.047h.673v5h-.673v-2.381H1.239v2.381H.56z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#90e050\" d=\"m83.637 17.831-5.186 2.995\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m10.862 18.28 4.795 2.769\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":null,"Title":"Flurbiprofen","Toxicity Data":"LD50: 10 mg/kg (Oral, Dog) (A308)","Treatment":"Patients should be managed by symptomatic and supportive care following overdose with a nonsteroidal anti-inflammatory drug. There are no specific antidotes. Emesis and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms, or following a large overdose (5 to 10 times the usual dose). Forced diuresis, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding. (L1712)","UNII":"5GRO578KLP","Wikidata":"Q419890","Wikipedia":"Flurbiprofen","XLogP":4.2}